Saltar al contenido
Merck

Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.

Bioorganic & medicinal chemistry letters (2006-06-01)
Zhiqin Ji, Asma A Ahmed, Daniel H Albert, Jennifer J Bouska, Peter F Bousquet, George A Cunha, Keith B Glaser, Jun Guo, Junling Li, Patrick A Marcotte, Maria D Moskey, Lori J Pease, Kent D Stewart, Melinda Yates, Steven K Davidsen, Michael R Michaelides
RESUMEN

A series of isothiazolopyrimidines and isoxazolopyrimidines were synthesized and identified as potent KDR inhibitors. SAR studies led to isothiazolopyrimidine urea analogs that potently inhibit VEGFR tyrosine kinases (KDR enzymatic and cellular IC(50) values below 10 nM) as well as cKIT and TIE2. The selected compounds 8 and 13 display 56% and 48% oral bioavailability in mice, respectively.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
2-Fluoro-5-(trifluoromethyl)phenyl isocyanate, 97%